|Articles|September 13, 2010

FDA on CV Risk in Diabetics

The FDA Guidance released in 2008 offers industry insight to why evaluation of heart risk in clinical trials is necessary.

ICE E-14 Step 2

Guidance for Industry

Integrated Cardiovascular Safety

Early Accuracy in New Drug Safety Analysis

Cardiac Safety: The Merits of ECG Centralization

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Content

Addressing Preclinical Gaps to Prevent Biotech Trial Delays

ByBen Edwards,Andy Studna, Senior Editor

October 15th 2025

Reframing the IND: From Tactical Requirement to Strategic Opportunity

ByMichael F Murphy, MD, PhD

October 15th 2025

Enhancing Data Quality and Real-World Evidence in Clinical Research

ByAndy Studna, Senior Editor

October 14th 2025

Answering the Sustainability Call: Digital Health Technologies and eCOA

ByEstelle Haenel, PharmD, PhD,Farrell Healion,Scottie Kern

October 14th 2025

Are Clinical Trial Diversity Initiatives at Risk of Being Dismantled?

ByRebecca Johnson, PhD

October 14th 2025

FDA on CV Risk in Diabetics

Newsletter

Related Content

Addressing Preclinical Gaps to Prevent Biotech Trial Delays

Reframing the IND: From Tactical Requirement to Strategic Opportunity

Enhancing Data Quality and Real-World Evidence in Clinical Research

Answering the Sustainability Call: Digital Health Technologies and eCOA

Are Clinical Trial Diversity Initiatives at Risk of Being Dismantled?

Trending on Applied Clinical Trials Online

Are Clinical Trial Diversity Initiatives at Risk of Being Dismantled?

Answering the Sustainability Call: Digital Health Technologies and eCOA

KRI Overload: When More Isn’t Better

Applied Clinical Trials' 2025 State of the Industry Survey

Enhancing Data Quality and Real-World Evidence in Clinical Research